Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
7.08
+0.05 (0.70%)
Real-time:   11:04AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.00 - 7.25
52 week 3.10 - 7.84
Open 7.03
Vol / Avg. 182,450.00/695,099.00
Mkt cap 492.38M
P/E 148.81
Div/yield     -
EPS 0.05
Shares 69.56M
Beta 1.72
Inst. own 89%
Mar 11, 2015
Q4 2014 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 24, 2015
Progenics Pharmaceuticals Inc at RBC Healthcare Conference
Feb 10, 2015
Progenics Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 12, 2015
Progenics Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 88.76% -541.49%
Operating margin 88.19% -546.68%
EBITD margin - -534.74%
Return on average assets 97.41% -44.61%
Return on average equity 126.74% -58.50%
Employees 69 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. is a medicine developing company. The Company is engaged in developing medicines for oncology. Its focus for Progenics is targeted therapeutics and imaging agents. The Company�s clinical development efforts center on late-stage oncology assets. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. The Company�s product, Relistor, is a treatment for opioid-induced constipation (OIC). PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a Phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert J. Israel M.D. Executive Vice President - Medical Affairs
Age: 57
Bio & Compensation  - Reuters
John W. Babich Ph.D. Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 61
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 57
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
David E. Martin J.D. General Counsel
Age: 59
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters